Celldex Therapeutics Inc. (CLDX) is scheduled to present 52-week results of its phase II trial of Barzolvolimab in patients with moderate to severe chronic spontaneous urticaria at the European Academy of Dermatology and Venereology Congress on Sep.25, 2024.
Chronic Spontaneous Urticaria is a skin disease characterized by the presence of hives or wheals lasting for six weeks or more without a clear trigger or cause. This condition involves the activation of mast cells in the skin, leading to the release of histamines, leukotrienes, and chemokines. As a result, patients experience persistent itching, swelling, and skin inflammation, which can continue for years or even decades.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.